Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02229461 · ClinicalTrials.gov registry record · Phase 1
Naproxen Sodium/ASA Platelet Study
A Phase 1 study of Hematology, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
- 1
- Study location
NCT02229461 is a Phase 1 study of Hematology that has completed, run by Bayer. The registered enrollment target is 117 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02229461, a Phase 1 study of Hematology, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if administration of naproxen sodium 220 mg maintains the platelet inhibitory effect of a low dose Immediate Release Aspirin (IR ASA) regimen.
Conditions Studied
Interventions
- DRUG Naproxen Sodium (Aleve, BAY117031)
- DRUG Acetylsalicylic Acid (Aspirin, BAYE4465)
Study Locations (1)
Texas
- - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02229461
The ClinicalTrials.gov registry entry for NCT02229461 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematology appearing as the primary indexed condition, and to 2 interventions - of which Naproxen Sodium (Aleve, BAY117031) is the first listed.
NCT02229461 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02229461 about?
NCT02229461 is a clinical study titled "Naproxen Sodium/ASA Platelet Study". To determine if administration of naproxen sodium 220 mg maintains the platelet inhibitory effect of a low dose Immediate Release Aspirin (IR ASA) regimen.
What is the current status of trial NCT02229461?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2015-02. Estimated completion is 2015-05.
What conditions does trial NCT02229461 study?
This clinical trial studies the following conditions: Hematology.
What interventions are being tested in trial NCT02229461?
The interventions under investigation include: Naproxen Sodium (Aleve, BAY117031) (DRUG), Acetylsalicylic Acid (Aspirin, BAYE4465) (DRUG).
Who is sponsoring clinical trial NCT02229461?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02229461 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematology
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.